BTIG Research Issues Positive Forecast for Boston Scientific (NYSE:BSX) Stock Price

Key Points

• BTIG Research has raised its target price for Boston Scientific stock from $127.00 to $132.00, indicating a potential upside of 35.32% from its previous close and maintaining a "buy" rating.
• Several analysts have also increased their price targets recently, with Wells Fargo setting theirs at $124.00 and Barclays reaching $133.00, reflecting widespread confidence in the company's growth potential.
• Boston Scientific posted a better-than-expected earnings report, with an EPS of $0.75 and a revenue of $5.06 billion, marking a 22.8% increase year-over-year.

Boston Scientific (NYSE:BSX - Get Free Report) had its target price upped by analysts at BTIG Research from $127.00 to $132.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a "buy" rating on the medical equipment provider's stock. BTIG Research's price target indicates a potential upside of 35.32% from the stock's previous close.

Other analysts also recently issued reports about the stock. Wells Fargo & Company lifted their price objective on shares of Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. Barclays lifted their price target on Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a report on Thursday, July 24th. Oppenheimer raised Boston Scientific from a "market perform" rating to an "outperform" rating and lifted their target price for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Royal Bank Of Canada restated an "outperform" rating and set a $125.00 price objective on shares of Boston Scientific in a research note on Monday. Finally, Truist Financial lifted their price objective on shares of Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Boston Scientific presently has an average rating of "Buy" and an average target price of $119.88.

Boston Scientific Stock Performance

BSX stock opened at $97.55 on Wednesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The stock has a market capitalization of $144.54 billion, a price-to-earnings ratio of 58.07, a PEG ratio of 2.34 and a beta of 0.65. Boston Scientific has a 1 year low of $80.64 and a 1 year high of $109.50. The stock's fifty day moving average is $103.53 and its two-hundred day moving average is $102.13.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm's quarterly revenue was up 22.8% compared to the same quarter last year. During the same period last year, the business posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts predict that Boston Scientific will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 124,214 shares of company stock valued at $13,048,957 over the last quarter. Company insiders own 0.50% of the company's stock.

Institutional Investors Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently modified their holdings of BSX. Norges Bank acquired a new stake in Boston Scientific during the 2nd quarter worth about $2,089,937,000. Edgewood Management LLC acquired a new stake in shares of Boston Scientific during the second quarter valued at approximately $746,655,000. Bessemer Group Inc. raised its holdings in shares of Boston Scientific by 14,391.8% during the second quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider's stock valued at $313,618,000 after acquiring an additional 2,899,653 shares during the period. Vanguard Group Inc. raised its holdings in shares of Boston Scientific by 1.9% during the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider's stock valued at $14,729,575,000 after acquiring an additional 2,545,381 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Boston Scientific by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock valued at $1,070,387,000 after acquiring an additional 1,664,108 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.